KRAS检验的全球市场 - 市场规模(各市场区隔)，占有率，法规，偿付，治疗，预测(～2033年)

本报告提供全球KRAS检验市场相关调查分析，提供各市场区隔的市场规模，市场趋势，竞争情形，COVID-19影响等资讯。

市场模式的主要内容如下列。

已上市的KRAS检验与不断变化的竞争格局

• 主要的产业趋势考察
• KRAS检验市场区隔的年度收益与市场预测(2015年～2033年)
• 台数，平均销售价格，市场金额相关市场层级的资料

世界，地区，国家层级的市场固有考察

• 各地区分类的全球趋势之定性市场固有资讯与各国考察
• KRAS检验市场SWOT分析
• KRAS检验市场竞争动态的考察和趋势

透过掌握包含医疗制度概要的真实整体状况来促进对市场的认识。此外在打入市场部门更提供关于给付原则及法规情势之资讯，使您能够更深入地研究市场动态。

• 各国医疗制度概要
• 各国偿付政策
• 各国医疗技术相关法规形势

对象企业

• F. Hoffmann-La Roche Ltd
• Qiagen NV
• Agilent Technologies Inc
• Illumina Inc
• Thermo Fisher Scientific Inc
• Abbott Laboratories
• NimaGen BV
• Mesa Laboratories Inc
• New England Biolabs Inc
• Amoy Diagnostics Co Ltd
• HLB PanaGene Co Ltd
• EntroGen, Inc
• Sysmex Corp
• Biocartis Group NV
• 其他

Abstract

KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on KRAS Tests market for the year 2020 and beyond. Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. In the United States, incidence and mortality are decreasing, while incidence rates are increasing in other parts of the world. The highest incidence rates are in Australia, New Zealand, Europe, and North America, while the lowest rates are found in Africa and South-Central Asia. These geographic differences can be attributed to diet, environmental exposure, and genetics.

Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking. With a dramatic increase in cigarette smoking rates, especially in China.

Kirsten Rat Sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation. It is commonly mutated in both CRC (39%) and NSCLC (25%) with the most frequent mutations in codons 12 and 13 causing over-activation of KRAS, which results in excessive cellular proliferation and tumor growth. While similar KRAS mutations are found in CRC and NSCLC, the frequency of the mutations differs between the two cancer types. In NSCLC, KRAS mutations are observed at a higher frequency in patients who have had significant exposure to tobacco.

The model covers KRAS Sanger sequencing Tests, KRAS Nucleic Acid Amplification Tests (NAAT) and KRAS Other Tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed KRAS Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total KRAS Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for KRAS Tests market.
• Competitive dynamics insights and trends provided for KRAS Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, EntroGen, Inc, Sysmex Corp, Biocartis Group NV, and others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the KRAS Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on KRAS Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving KRAS Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific KRAS Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable